The company offers HLM0022, a compound drug for the treatment of ophthalmic surgery. It is also developing cellular and tissue-based products comprising HLM0021 indicated for vitreous and cataract surgeries; HLM0023 indicated for vitreous surgery; and HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration. Healios K.K. was founded in 2011 and is headquartered in Tokyo, Japan.